SRR934832
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 38.3377135348226
- age_years
- 39
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.446
- ALLOGRAFT_REJECTION+0.416
- INTERFERON_GAMMA_RESPONSE+0.407
- PROTEIN_SECRETION+0.384
- MITOTIC_SPINDLE+0.379
- IL6_JAK_STAT3_SIGNALING+0.359
- COMPLEMENT+0.338
- INFLAMMATORY_RESPONSE+0.319
- TGF_BETA_SIGNALING+0.318
- IL2_STAT5_SIGNALING+0.314
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.459
- KRAS_SIGNALING_DN-0.328
- OXIDATIVE_PHOSPHORYLATION-0.198
- MYOGENESIS-0.177
- SPERMATOGENESIS-0.148
- HEDGEHOG_SIGNALING-0.139
- MYC_TARGETS_V2-0.128
- ESTROGEN_RESPONSE_LATE-0.053
- DNA_REPAIR-0.048
- ESTROGEN_RESPONSE_EARLY-0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934830 | — | — | 0.928 |
| 2 | SRR934807 | — | — | 0.912 |
| 3 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.909 |
| 4 | SRR934942 | — | — | 0.909 |
| 5 | CB1F8B9C-7CE7-4181-B746-7FC697ED27F4 | — | — | 0.905 |
| 6 | 722B7A0F-BF34-4368-8CFF-944FCBC7DAC4 | — | — | 0.899 |
| 7 | C1CCE12B-8892-49AB-8DF2-E5E280DEAE32 | — | — | 0.898 |
| 8 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.898 |
| 9 | SRR934811 | — | — | 0.894 |
| 10 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.446 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.416 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.407 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.384 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.379 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.359 | Inavolisib | — uncovered |
| COMPLEMENT | 0.338 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.319 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.318 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.314 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.306 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.299 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.295 | Inavolisib | — uncovered |
| APOPTOSIS | 0.292 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.241 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.231 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.228 | Inavolisib | — uncovered |
| COAGULATION | 0.218 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.207 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.201 | Inavolisib | — uncovered |